Durolane 3ml

Descrição

Durolane 3ml is a single-injection intra-articular viscosupplement containing 60 mg (20 mg/mL) of stabilized non-animal stabilized hyaluronic acid (NASHA) in a 3 mL pre-filled syringe. Manufactured by Bioventus (formerly Q-Med/Galderma), Durolane uses patented NASHA technology to create a highly concentrated, cross-linked HA gel with exceptional viscoelastic properties and durability. Once injected into the osteoarthritic knee joint, Durolane restores the viscoelasticity of synovial fluid, providing shock absorption, lubrication, and chondroprotection while reducing inflammation and pain signals.

Unlike multi-injection HA products (Synvisc-One, Hyalgan, Orthovisc), Durolane is specifically formulated for a single administration, simplifying treatment and improving patient compliance. Clinical studies (including randomized controlled trials and real-world registries) demonstrate that Durolane significantly reduces knee pain (measured by WOMAC, VAS, and KOOS scores), improves joint function, and enhances quality of life for up to 6 months in patients with mild to moderate knee osteoarthritis (Kellgren-Lawrence grades 1–3). Many patients report pain relief starting within 1–4 weeks, peaking around 2–3 months, and lasting 6 months or longer in responders.

Key Advantages

• Single-injection convenience (no need for 3–5 weekly injections)
• High molecular weight and concentration for prolonged residence time in the joint
• Excellent safety profile with low immunogenicity (non-animal origin)
• Minimal systemic absorption
• Suitable for patients who failed conservative therapy (NSAIDs, physical therapy, weight loss) and wish to delay or avoid knee replacement

Administration

Durolane 3ml is administered as a single intra-articular injection into the affected knee by a qualified healthcare professional (orthopedic surgeon, rheumatologist, or pain specialist). The procedure is performed under aseptic conditions, often with local anesthesia or ultrasound guidance for precise placement. No joint aspiration is required prior to injection.

Common Side Effects & Safety

Most side effects are mild and transient (resolving within days to 2 weeks):

• Injection-site pain, swelling, warmth, or stiffness
• Mild arthralgia or effusion
• Temporary increase in pain (post-injection flare)

Rare complications include infection (septic arthritis), severe allergic reactions, or significant effusion requiring aspiration. Durolane is contraindicated in patients with known hypersensitivity to hyaluronic acid preparations, active joint infection, or skin infection at the injection site. It is not indicated for joints other than the knee in most approved regions (though off-label use in hip, ankle, shoulder, and thumb OA occurs in some countries).

As of 2026, Durolane is approved in the European Union, Canada, Australia, many Asian and Latin American countries, and numerous other markets, but it is not FDA-approved in the United States (where similar single-injection HA products include Synvisc-One and Monovisc). It should only be administered by licensed medical professionals trained in intra-articular injection techniques.

Always combine Durolane treatment with a comprehensive osteoarthritis management plan: weight management, physical therapy, low-impact exercise, pain management strategies, and joint protection techniques. Consult an orthopedic specialist or rheumatologist for a thorough evaluation, to confirm if Durolane is appropriate for your knee osteoarthritis, and to discuss expected outcomes, risks, and alternatives (including other viscosupplements, corticosteroid injections, PRP, or surgical options).